Kensuke Nakamura

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 4

Top Topics

Monoclonal Antibody

Advanced Non Small Cell Lung Cancer

Dna Damage Response

Top Venues

Nature communications

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Hirokazu Suzuki, Shotaro Nagase, Chiemi Saito, Atsuko Takatsuka, Motoko Nagata, Kokichi Honda, Yuki Kaneda, Yumi Nishiya, Tomoyo Honda, Tomomichi Ishizaka, Kensuke Nakamura, Takashi Nakada, Yuki Abe, Toshinori Agatsuma
Raludotatug Deruxtecan, a CDH6-Targeting Antibody-Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, is Efficacious in Human Ovarian and Kidney Cancer Models. Molecular cancer therapeutics (2024)
Hirokazu Suzuki, Shotaro Nagase, Chiemi Saito, Atsuko Takatsuka, Motoko Nagata, Kokichi Honda, Yuki Kaneda, Yumi Nishiya, Tomoyo Honda, Tomomichi Ishizaka, Kensuke Nakamura, Takashi Nakada, Yuki Abe, Toshinori Agatsuma
Raludotatug Deruxtecan, a CDH6-Targeting Antibody-Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models. Molecular cancer therapeutics 23 (3) (2024)
Takenobu Katagiri, Sho Tsukamoto, Mai Kuratani, Shinnosuke Tsuji, Kensuke Nakamura, Satoshi Ohte, Yoshirou Kawaguchi, Kiyosumi Takaishi
Publisher Correction: A blocking monoclonal antibody reveals dimerization of intracellular domains of ALK2 associated with genetic disorders. Nature communications 14 (1) (2023)
Takenobu Katagiri, Sho Tsukamoto, Mai Kuratani, Shinnosuke Tsuji, Kensuke Nakamura, Satoshi Ohte, Yoshirou Kawaguchi, Kiyosumi Takaishi
A blocking monoclonal antibody reveals dimerization of intracellular domains of ALK2 associated with genetic disorders. Nature communications 14 (1) (2023)